Login to Your Account



'Nant' Worth it: Merck Scraps Phase III, but Whither Biotie?

By Randy Osborne
Staff Writer

Friday, May 24, 2013
The decision by Merck & Co. Inc. to end its Phase III program with preladenant based on three studies that failed to show efficacy in Parkinson's disease put the spotlight on adenosine A2A receptor antagonists as a class, which has been explored by a handful of other companies, some of them with work still under way.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription